Becton, Dickinson and Co.
BDX Real Time Price USDRecent trades of BDX by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BDX holdings by institutional investors
Quarterly net insider trading by BDX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$622,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign)
-
$755,000 Apr 20, 2026 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Budget/Appropriations
-
$1,496,000 Jan 15, 2026 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Medicare/Medicaid
-
$550,000 Oct 17, 2025 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign) Medicare/Medicaid
-
$1,438,000 Oct 14, 2025 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign)
-
$557,000 Sep 15, 2025 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign)
-
$485,000 Jan 21, 2025 Issue: Budget/Appropriations Trade (domestic/foreign) Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$400,000 Oct 21, 2024 Issue: Trade (domestic/foreign) Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$427,000 Jul 22, 2024 Issue: Trade (domestic/foreign) Budget/Appropriations Taxation/Internal Revenue Code Health Issues
-
$60,000 Feb 07, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Budget/Appropriations
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$10,000 Oct 19, 2023 Issue: Trade (domestic/foreign)
-
$80,000 Oct 18, 2023 Issue: Health Issues
-
$60,000 Oct 17, 2023 Issue: Environment/Superfund Medicare/Medicaid Health Issues Budget/Appropriations
-
$10,000 Oct 06, 2023 Issue: Trade (domestic/foreign)
-
$80,000 Jul 20, 2023 Issue: Health Issues
-
$60,000 Jul 17, 2023 Issue: Environment/Superfund Medicare/Medicaid Health Issues Budget/Appropriations
-
$80,000 Jan 20, 2023 Issue: Health Issues
-
$60,000 Jan 20, 2023 Issue: Health Issues
-
$20,000 Jan 10, 2023 Issue: Health Issues
-
$80,000 Oct 20, 2022 Issue: Health Issues
-
$60,000 Oct 20, 2022 Issue: Health Issues
-
$60,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Budget/Appropriations
-
$50,000 Oct 19, 2022 Issue: Health Issues
-
$50,000 Jul 21, 2022 Issue: Health Issues
-
$80,000 Jul 20, 2022 Issue: Health Issues
-
$60,000 Jul 19, 2022 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$60,000 Jul 18, 2022 Issue: Health Issues
-
$80,000 Apr 20, 2022 Issue: Health Issues
-
$60,000 Apr 15, 2022 Issue: Health Issues
-
$60,000 Apr 14, 2022 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$50,000 Apr 11, 2022 Issue: Health Issues
-
$80,000 Jan 20, 2022 Issue: Health Issues
-
$60,000 Jan 19, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Budget/Appropriations
-
$40,000 Jan 18, 2022 Issue: Health Issues
-
$60,000 Jan 15, 2022 Issue: Health Issues
-
$80,000 Oct 20, 2021 Issue: Health Issues
-
$40,000 Oct 20, 2021 Issue: Health Issues
-
$60,000 Oct 18, 2021 Issue: Health Issues
-
$60,000 Oct 18, 2021 Issue: Health Issues Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid
-
$100,000 Feb 12, 2007 Issue: Budget/Appropriations Health Issues
-
$100,000 Aug 07, 2006 Issue: Budget/Appropriations
-
$80,000 Feb 09, 2006 Issue: Budget/Appropriations
-
$100,000 Aug 15, 2005 Issue: Health Issues Budget/Appropriations
-
$240,000 Aug 15, 2005 Issue: Health Issues
-
$20,000 Aug 08, 2005 Issue: Taxation/Internal Revenue Code
-
$440,000 Aug 26, 2004 Issue: Health Issues
-
$340,000 Apr 13, 2004 Issue: Health Issues
-
$260,000 Aug 15, 2003 Issue: Health Issues
-
$180,000 Mar 03, 2003 Issue: Health Issues
-
$260,000 Aug 14, 2002 Issue: Health Issues
-
$200,000 Feb 14, 2002 Issue: Health Issues
-
$140,000 Aug 22, 2001 Issue: Health Issues
-
$160,000 Feb 15, 2001 Issue: Health Issues
-
$160,000 Aug 15, 2000 Issue: Health Issues
-
$80,000 Feb 16, 2000 Issue: Health Issues
Former government officials who have lobbied for BDX
27 former government officials from 14 congressional offices at 4 lobbying firms have lobbied for BDX, most recently Jul 20, 2026.
-
John Stone House Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
-
Joseph Lai Senate Sp. Asst. to POTUS for Leg Affairs; LD Sen. Wicker; Mil. Leg. Asst. Sen Wicker; Policy Advisor Sen. Voinovich; Policy Advisor Sen. Hagel; Intern U.S. Trade and Development Agency -
David Urban Senate COS Sen. Specter; 11th Chair of the Ame. Battle Monuments Comm.; USMA Board of Visitors -
Steven Pfrang House COS, Rep. LaHood; Dep COS, LD, Rep. Reed; LA, LC, SA, Intern, Rep. Fossella
-
Hunter Strupp House Staff Dir, Subcommittee on Asia and the Pacific; Asia Policy Analyst, HFAC; Staff Asst, Terrorism, Nonproliferation and Trade Subcommittee; Leg Asst, Rep. Ed Royce; Leg Corr, Rep. Ed Royce; Intern, Subcommittee on Africa -
William Crozer Other Special Assistant to the President for Intergovernmental Affairs
-
Maya Seiden House Intern, WH Counsels Office; Intern, Rep. Sam Gejdenson; Sp. Asst to Cab Sec., WH; Advisor to CoS, Energy Dept.; Sp Asst to Sec of Energy; Sen Advisor, Off of Dep. Sec of State; CoS Office of the Dep Sec of State for Management and Res. -
James Williams Other Special Asst. to the Pres., WH Domestic Policy Council, 2019-2021; Economist, WH Council of Economic Advisors, 2017-2019
BDX Estimated quarterly lobbying spending
BDX Revenue by Segment or Geography
New BDX patent grants
-
Patent Title: Accurate molecular barcoding Oct. 14, 2025
-
Patent Title: Syringe adapter Sep. 12, 2023
-
Patent Title: Display screen with graphical user interface Sep. 05, 2023
-
Patent Title: Display screen with graphical user interface Sep. 05, 2023
-
Patent Title: Display screen with graphical user interface Aug. 08, 2023
-
Patent Title: Sample rack adapter Jul. 25, 2023
-
Patent Title: Syringe device Jun. 13, 2023
-
Patent Title: Display screen or portion thereof with a graphical user interface for a test platform Jun. 13, 2023
-
Patent Title: Sample preparation module Feb. 28, 2023
-
Patent Title: Microfluidic cartridge Feb. 21, 2023
-
Patent Title: Catheter system having a pinch clamp Feb. 07, 2023
-
Patent Title: Collection device Jan. 24, 2023
-
Patent Title: System and method for adjusting cytometer measurements Jan. 17, 2023
-
Patent Title: Cartridge imaging background device Nov. 15, 2022
-
Patent Title: Tip cap and disinfecting unit Oct. 04, 2022
-
Patent Title: Injection site tool Sep. 13, 2022
-
Patent Title: Venous finite element analysis tool Aug. 09, 2022
-
Patent Title: Reagent plate Jul. 26, 2022
-
Patent Title: Syringe device Jun. 07, 2022
-
Patent Title: Medical stopper May. 03, 2022
-
Patent Title: Display screen or portion thereof with a graphical user interface for a test platform Mar. 22, 2022
-
Patent Title: Spatially addressable molecular barcoding Feb. 01, 2022
-
Patent Title: Display screen or portion thereof with graphical user interface for managing diabetes Oct. 12, 2021
-
Patent Title: Display screen or portion thereof with a graphical user interface for an integrated disease management system Oct. 12, 2021
-
Patent Title: Vessel assembly Sep. 28, 2021
-
Patent Title: Medical vial access device Sep. 14, 2021
-
Patent Title: Catheter hub device Aug. 31, 2021
-
Patent Title: Process plate Jul. 20, 2021
-
Patent Title: Enteral syringe Jul. 20, 2021
-
Patent Title: Enteral syringe Jul. 20, 2021
-
Patent Title: Reagent plate Jun. 29, 2021
-
Patent Title: Combined cap and septum assembly for a vessel Jun. 29, 2021
-
Patent Title: Security clamp for medical device Jun. 29, 2021
-
Patent Title: Medical connector Jun. 29, 2021
-
Patent Title: Collection device Jun. 22, 2021
-
Patent Title: Pinch clamp Jun. 08, 2021
-
Patent Title: Reagent plate May. 25, 2021
-
Patent Title: Sample preparation module May. 25, 2021
-
Patent Title: Diagnostic testing module May. 25, 2021
-
Patent Title: Process plate May. 18, 2021
-
Patent Title: Septum for a vessel Apr. 27, 2021
-
Patent Title: Passively activated safety needle assemblies and methods of use Jun. 16, 2020
-
Patent Title: Passively activated safety needle assemblies and methods of use Jul. 02, 2019
-
Patent Title: Method and apparatus for manufacturing, filling and packaging medical devices and medical containers Aug. 15, 2017
-
Patent Title: Systems and methods for providing a catheter assembly Feb. 23, 2016
-
Patent Title: Needle safety device Jun. 12, 2012
-
Patent Title: Syringe barrel Nov. 22, 2011
-
Patent Title: Collection container Oct. 18, 2011
-
Patent Title: Specimen collection container having a label Sep. 27, 2011
-
Patent Title: Needle hub Sep. 06, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded to BDX from public contracts
Recent insights relating to BDX
Recent picks made for BDX stock on CNBC
ETFs with the largest estimated holdings in BDX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BDX stock a Buy, Sell, or Hold?
- What is the price target for $BDX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BDX stock?
- Who owns the most shares of $BDX stock?
- What funds own $BDX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
- Address Franklin Lakes, NJ
- Market Cap 49.4 billion
- Employees 72,000
- Industrial Classification Surgical & Medical Instruments & Apparatus
We estimate that -- received a compensation of -- in --, making them the highest paid executive at BDX, per a recent SEC DEF 14A filing. We estimate that the median employee at BECTON DICKINSON & CO is paid $43,763.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|